MUNICH, GERMANY - Aug 4, 2016 - Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, today announced the release of its Clinical Development Offering, making the company the premier provider of comprehensive tissue-based services from discovery to commercialization. The new service enables pharmaceutical companies to improve patient outcomes and reduce pipeline risk, ultimately moving therapies to market more quickly and improving the success of drug programs.

Leveraging Tissue Phenomics, Definiens provides robust and precise quantitative IHC, ISH, and IF assays to identify tissue features in context that can be easily combined with other data types to mine for clinically relevant patterns.

“The focus of our new Definiens clinical development offering is to support our partners in maximizing their pipeline, to accurately identify patient populations and therefore deliver the right therapy,” said Thomas Heydler, CEO, Definiens. “We are now providing image analysis, data mining and assay development, combined with deep scientific, regulatory and pathology support. It’s truly an end-to-end offering for biopharma,” he adds.

The Clinical Development Offering provides a number of services:

Clinical Trial Services

• Drive Pipeline Decisions: Gain biological insights from custom tissue-based assays & quantitative image analysis solutions to drive pipeline decisions in your clinical trials.

Signature Discovery Services

• Discover the Best Signatures: Utilize our unparalleled data mining on your tissue samples to find novel signatures and assess the potential of a biomarker to identify patient populations.

Companion Diagnostics Services

• Deliver Precise CDx to the Market:  With precise quantitative biomarker readouts, best-in-class, co-developed assays ensure fast movement from prototype to regulatory filing.

To learn more about Definiens’ Clinical Development Offering, please contact us. For more information about Definiens, visit www.definiens.com.